Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review

被引:8
作者
Atallah, Richard Teofilo [1 ]
Castanos, Maria Virginia [2 ,3 ]
Najac, Richard [2 ]
Donnenfeld, Eric [4 ]
机构
[1] Rutgers New Jersey Med Sch, Newark, NJ USA
[2] Eye & Ear Infirm Mt Sinai, Dept Res, New York, NY USA
[3] New York Eye & Ear Infirm Mt Sinai, Dept Ophthalmol, New York, NY USA
[4] NYU, Med Ctr, Ophthalm Consultants Long Isl, Garden City, NY USA
关键词
lifitegrast; integrin antagonist; dry eye disease; DED; eye dryness; inflammation; ocular surface disease; OPHTHALMIC SOLUTION 5.0-PERCENT; DISEASE; PLACEBO;
D O I
10.2147/OPTH.S191635
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate 6-month treatment benefits with lifitegrast ophthalmic solution 5% in symptomatic dry eye patients. Setting: Retrospective chart analysis. Method: A retrospective chart review was conducted in 168 patients (111 females and 57 males) who presented with symptoms of chronic dry eye disease and were treated with lifitegrast 5% ophthalmic solution for 6 months. Collected symptom data included improvement of eye dryness, tearing, eye pain, fluctuation in vision, foreign body sensation, itching, grittiness, burning and contact lens intolerance if applicable. Collected clinical signs included changes in superficial punctate keratitis, corneal fluorescein staining, conjunctival hyperemia and presence of tear debris. Results: Treatment with lifitegrast ophthalmic solution 5% twice daily for 6 months significantly improved majority of dry eye symptoms reported by patients. Improvements were also observed in corneal and conjunctival staining and tear debris for most of the patients reviewed. Conclusion: Treatment with lifitegrast twice a day for 6 months improved both signs and symptoms of chronic dry eye.
引用
收藏
页码:1033 / 1037
页数:5
相关论文
共 11 条
[1]  
[Anonymous], 2016, SHIRE JUL
[2]   TFOS DEWS II Definition and Classification Report [J].
Craig, Jennifer P. ;
Nichols, Kelly K. ;
Akpek, Esen K. ;
Caffery, Barbara ;
Dua, Harminder S. ;
Joo, Choun-Ki ;
Liu, Zuguo ;
Nelson, J. Daniel ;
Nichols, Jason J. ;
Tsubota, Kazuo ;
Stapleton, Fiona .
OCULAR SURFACE, 2017, 15 (03) :276-283
[3]   Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study [J].
Donnenfeld, Eric D. ;
Karpecki, Paul M. ;
Majmudar, Parag A. ;
Nichols, Kelly K. ;
Raychaudhuri, Aparna ;
Roy, Monica ;
Semba, Charles P. .
CORNEA, 2016, 35 (06) :741-748
[4]   Lifitegrast for the Treatment of Dry Eye Disease Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3) [J].
Holland, Edward J. ;
Luchs, Jodi ;
Karpecki, Paul M. ;
Nichols, Kelly K. ;
Jackson, Mitchell A. ;
Sall, Kenneth ;
Tauber, Joseph ;
Roy, Monica ;
Raychaudhuri, Aparna ;
Shojaei, Amir .
OPHTHALMOLOGY, 2017, 124 (01) :53-60
[5]   Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials [J].
Holland, Edward J. ;
Whitley, Walter O. ;
Sall, Kenneth ;
Lane, Stephen S. ;
Raychaudhuri, Aparna ;
Zhang, Steven Y. ;
Shojaei, Amir .
CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (10) :1759-1765
[6]   TFOS DEWS II Management and Therapy Report [J].
Jones, Lyndon ;
Downie, Laura E. ;
Korb, Donald ;
Benitez-del-Castillo, Jose M. ;
Dana, Reza ;
Deng, Sophie X. ;
Dong, Pham N. ;
Geerling, Gerd ;
Hida, Richard Yudi ;
Liu, Yang ;
Seo, Kyoung Yul ;
Tauber, Joseph ;
Wakamatsu, Tais H. ;
Xu, Jianjiang ;
Wolffsohn, James S. ;
Craig, Jennifer P. .
OCULAR SURFACE, 2017, 15 (03) :575-628
[7]   Long-term Natural History of Dry Eye Disease from the Patient's Perspective [J].
Lienert, Jeffrey P. ;
Tarko, Laura ;
Uchino, Miki ;
Christen, William G. ;
Schaumberg, Debra A. .
OPHTHALMOLOGY, 2016, 123 (02) :425-433
[8]   Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease [J].
Perez, Victor L. ;
Pflugfelder, Stephen C. ;
Zhang, Steven ;
Shojaei, Amir ;
Haque, Reza .
OCULAR SURFACE, 2016, 14 (02) :207-215
[9]   LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease [J].
Pflugfelder, Stephen C. ;
Stern, Michael ;
Zhang, Steven ;
Shojaei, Amir .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2017, 33 (01) :5-12
[10]  
Tauber J, 2018, ISOPT CLIN MARCH 1 3